Morgan Stanley decreased its holdings in shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) by 19.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 167,362 shares of the biotechnology company’s stock after selling 39,393 shares during the quarter. Morgan Stanley owned about 0.40% of Aclaris Therapeutics worth $367,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the business. Aperio Group LLC purchased a new position in Aclaris Therapeutics in the second quarter valued at $33,000. Marshall Wace LLP purchased a new position in Aclaris Therapeutics in the first quarter valued at $103,000. DekaBank Deutsche Girozentrale boosted its holdings in Aclaris Therapeutics by 66.9% in the second quarter. DekaBank Deutsche Girozentrale now owns 21,200 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 8,500 shares during the period. Alambic Investment Management L.P. purchased a new position in Aclaris Therapeutics in the second quarter valued at $115,000. Finally, Parametric Portfolio Associates LLC boosted its holdings in Aclaris Therapeutics by 58.8% in the second quarter. Parametric Portfolio Associates LLC now owns 90,867 shares of the biotechnology company’s stock valued at $199,000 after purchasing an additional 33,646 shares during the period. 84.76% of the stock is owned by institutional investors.
A number of research analysts recently issued reports on the company. William Blair reiterated a “buy” rating on shares of Aclaris Therapeutics in a report on Friday, October 11th. JMP Securities lowered Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, September 6th. Leerink Swann upgraded Aclaris Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, October 22nd. Zacks Investment Research lowered Aclaris Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $5.00 target price (down from $24.00) on shares of Aclaris Therapeutics in a report on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $6.50.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.80). The business had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $5.87 million. Aclaris Therapeutics had a negative return on equity of 83.22% and a negative net margin of 1,165.39%. Research analysts forecast that Aclaris Therapeutics Inc will post -2.98 EPS for the current fiscal year.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics Inc (NASDAQ:ACRS).
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.